Pfizer Medicare Part D Negotiations Not Focusing On Dual-Eligible Plans
Executive Summary
Pfizer is not prioritizing preferred tier positioning in negotiations with Medicare Part D drug plans expected to enroll large numbers of dual-eligibles due to the limited difference in brand tier copays for such beneficiaries
You may also be interested in...
Part D Plans With Most Enrollees Getting Deeper Discounts In ’07 – Astra Exec
The Medicare Part D prescription drug plans that enrolled the largest number of beneficiaries in 2006 have generally been able to extract deeper discounts from manufacturers in the second year of the drug benefit, AstraZeneca U.S. CEO Tony Zook said in an interview with "The Pink Sheet."
Part D Plans With Most Enrollees Getting Deeper Discounts In ’07 – Astra Exec
The Medicare Part D prescription drug plans that enrolled the largest number of beneficiaries in 2006 have generally been able to extract deeper discounts from manufacturers in the second year of the drug benefit, AstraZeneca U.S. CEO Tony Zook said in an interview with "The Pink Sheet."
Pfizer Medicare Part D Formulary Placement: Bundled Up, Or Out In The Cold?
Pfizer appears to have taken an all-or-nothing approach to negotiating formulary positioning for its products in Medicare Part D prescription drug plans, according to an analysis by "The Pink Sheet" of plan formularies